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Abstract
Background: HLA-G gene is a non-classical MHC class 1 molecule that is highly expressed in the
trophoblast at the maternal-fetal interface. In an attempt to elucidate possible immunological
mechanisms facilitating protection of infants born to human immunodeficiency virus type (HIV-1)
infected mothers, we have been studying genetic variations in the coding and untranslated regions
of HLA-G antigen between HIV-1-infected mothers and their infected or uninfected infants. This
study investigated whether HLA-G DNA sequence variants are associated with perinatal HIV-1
transmission.
Results: Genomic DNA samples were obtained from a nested case-control study of 34 mother-
child pairs co-enrolled in a cohort of the Perinatal AIDS Collaborative Transmission Study in New
York. The samples were from two groups predominantly of African-American and Hispanic origin:
In the first group, both mother and child were HIV-1-infected; in the second group, only the mother
was infected while the child remained uninfected. Genotyping of HLA-G gene were performed on
the extracted DNA from peripheral blood mononuclear cells using PCR based sequencing and
restriction fragment-length polymorphism analyses.
Among the studied HLA-G exons, dissimilarities in HLA-G DNA sequence variants between the
HIV-1 non-transmitting mother child pairs were mostly observed in exon 8-3'-untranslated region
at nucleotide positions T3742A, C3743T, G3777C (P = 0.001). Non-transmitting HIV-1 mother
child pairs exhibited dissimilarities at nucleotide position C3743T allele with decreased risk of
perinatal HIV-1 transmission, compared with HIV-1 transmitting mother-child pairs carrying this
allele (odds ratio 0.02 [95% confidence interval 0.00–0.15] P = 0.00001). In addition, heterozygous
dissimilarities at nucleotide positions C634G and 714 insT/G in the 5'-upstream regulatory region
were observed between the mother child pairs of the HIV-1-non-transmitting group while
homozygous similarities of C634C, and either 714insG/G or mother-child pairs with similar
714insT/G were observed among the transmitting group in the same region.
Conclusion: This study identified new variants in the HLA-G gene and provides further evidence
that dissimilarities in the HLA-G DNA sequence variants could influence the transmission of HIV-
1 from infected mothers to their infants.
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Background
Mother-to-child HIV transmission (MTCT) can occur dur-
ing pregnancy, labor and postnatally through breastfeed-
ing [1,2]. In developed countries, MTCT has decreased to
approximately 1 or 2% after implementation of universal
prenatal HIV counseling and testing, antiretroviral proph-
ylaxis, elective cesarean delivery and avoidance of breast-
feeding [3]. Antiretroviral therapy for infected pregnant
women has significantly reduced the risk of MTCT in
developing countries. However, factors primarily related
to logistics, costs and access have limited the impact of
these interventions in developing countries. Although it
remains important to continue to pursue strategies to
make effective antiretroviral interventions available in
developing countries, an efficacious vaccine would surely
be highly valuable for reduction of MTCT and certainly
would be the best strategy for reducing infection spread
worldwide among adults. The development of an effective
vaccine would be greatly assisted by better understanding
of the molecular genetic mechanisms of transmission,
including for example, if the host gene immune responses
involving the chemokines [4,5], and HLA polymorphisms
are involved in host-HIV-1 interactions.
Human leukocyte antigen G (HLA-G), a non-classical
class 1 MHC gene, is highly expressed in trophoblast at
the maternal-fetal interface. The unique expression of this
gene in the trophoblast at the maternal-fetal interface
indicates a critical role for this locus in human pregnancy.
Past studies [6-8] suggest that HLA-G gene protects the tro-
phoblast from maternal T-cell and natural killer cell (NK)
mediated lysis. However, association of this HLA-G gene
with HIV-1 infection or transmission is yet to be fully
determined. Several lines of evidence suggest that fetal or
newborn alloimmune responses directed at maternal
HIV-1-infected cells or at free virus bearing maternal MHC
determinants may account for some children remaining
uninfected [9-11]. A study by Arthur et al., [12] showed
that class 1 MHC antigens were present on the envelope of
HIV-1 and that the antisera to these proteins precipitated
intact virions [7]. Chan et al., [13] observed that immuni-
zation with purified class 1 HLA molecules could protect
macaques from challenge with cell-free virus expressing
the class 1 HLA  peptides [9]. During mother-to-child
transmission of HIV-1, it is unclear whether free HIV-1 vir-
ions or HIV-1-infected cells of maternal origin or both are
present in the maternal MHC antigens. It is possible that
either fetal or newborn anti-MHC or alloreactive T cell
responses could protect the infant against infection trans-
mitted from the mother. However, such mechanisms
would only be operative if there were some degree of
HLA-G sequence variants between the mother and the
child. The effects would depend on mechanisms and
changes in the function that resulted from the HLA-G
sequence variants. Moreover, it could reasonably be
expected that any protection provided may correlate with
the extent of HLA discordance between the mother and
the child as previously reported [9-11]. This study was
designed to examine variants in the HLA-G gene that may
play a role in perinatal HIV-1 transmission.
Methods
Study participation
A nested case-control study designed with subjects and
controls were selected from enrolled participants that
were previously followed as a part of Perinatal AIDS Col-
laborative Transmission Study (PACTS), a multi-center
cohort study of vertical HIV transmission, funded by
Centers for Disease Control and Prevention (CDC), which
enrolled 2,665 HIV-positive mother-infants between
1986 and 1998 (360 HIV-1-infected infants). In this
study, only participants enrolled in New York City were
part of the selection of 34 mother-child pairs. Generally,
PACTS cohorts collected early neonatal PCR data (< 48–
72 hours after birth) and classified the perinatally HIV-1-
infected infants in the cohort as: 1) intrauterine infection
(DNA PCR positive < 48 hours) and 2) presumed peripar-
tum infection (intrapartum and/or very late interuterine).
The study protocols have been approved by institutional
review boards at the respective participating sites includ-
ing the CDC. Written informed consent were obtained
from mothers who participated in this study.
Participation criteria
Blood samples were obtained from infants who were at
least after 2 months of age. Children known to have been
breast-fed or whose HIV-1 status could not be determined
were excluded. Also, all blood samples were from mother-
child pairs who were not treated with antiretroviral drugs.
The majority of samples included in this study were Afri-
can American (59%) and Hispanic (29%). The mean
birthweight among the infant participants were 2715
grams in the non-transmitting mother-child pairs and
2607 grams (p = 0.3) in transmitting mother-child pairs
and the mean maternal CD4+ T-lymphocyte count were
579 copies/mL and 488 copies/mL (p = 0.2) in the non-
transmitting and transmitting groups respectively. Pre-
term delivery of the infants (< 37 weeks) were 29% (4/14)
among the HIV-1-non-transmitting mothers and 30% (6/
20) (p = 0.8) among the HIV-1-transmitting mothers. The
CD4+:CD8+ ratio was 0.9 [(0.61), 21.4% (3/14)] and 0.59
[(0.36) 5% (1/20)] (p = 0.5) among the non-transmitting
and transmitting mothers respectively. In addition, rup-
ture of membranes during delivery was 50% (7/14)
among the HIV-1-non-transmitting and 55% (11/20) (p =
0.9) among the HIV-1-transmitting mothers. Mothers
diagnosed with AIDS before delivery were 21.4% (3/14)
among the non-transmitting group and 25% (5/20) (p =
0.8) among transmitting group.AIDS Research and Therapy 2006, 3:28 http://www.aidsrestherapy.com/content/3/1/28
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Study protocol
Genomic DNA samples were isolated from the blood
drawn within 48 hours to 18 months after birth from the
participated infants for HIV-1 PCR-based tests. Children
enrolled in this study were tested again at months 1, 2, 4,
and 6 and at a month interval thereafter. The cohorts fol-
lowed all infected children and examined them at regular
intervals according to the standard protocols: children
were considered infected if they were HIV-1-seropositive,
confirmed by western blot at ≥18 months of age, had two
or more positive PCR tests or viral cultures at any age, had
an AIDS-defining illness, or if they died with HIV-related
condition [14].
Sample source and DNA extraction
Extracted DNA were obtained from blood samples of 34
mother-child pairs, which included 20 HIV-1-infected
mother-child pairs, and 14 infected mother-uninfected
child pairs. Briefly, blood samples were collected in vacu-
tainer collection tubes containing EDTA anticoagulant.
Plasma and peripheral blood mononuclear cell (PBMC)
fractions were prepared by Ficoll-Hypaque centrifugation.
Cells in the PBMC fraction were washed in phosphate
buffered saline (PBS). The PBMCs were lysed and
genomic DNA were purified using the QIAamp blood
PCR Kit (Qiagen, Chatsworth, CA), and quantified by UV
absorption spectrometry. DNA was stored at -20°C.
Amplification of HLA-G exons, intron, 5'URR and 8-3'UTR
Isolated genomic DNA samples from HIV-1-infected
mother/child pairs were amplified using HLA-G  allele-
specific primers as previously described [7,15] for exons 3,
and 4. Extensive care was taken to design primers for
5'untranslated regulatory region (5'URR) and primers
spanning exons 6, 7 and 8-3' untranslated regions (8-
3'UTR) using previously described nucleotide sequence of
HLA-6.0 by Geraghty et al. [16]. Primers for 5'URR,
(5hlag1F:  5'-GGGTTTCTC CCTGGTTTCTC-3' (forward)
and  3hlagex1R 5-CGAGGAGGGGTTGAGACC -3'
(reverse)), generated a 550-bp fragment as a part of 5'URR
that spanned exon 1. Primers for 8-3'UTR, (5hlaf6/7: 5'-
TTCCTCTAGGACCTCATGGCC-3' (forward) and 3hlagex8
5'-AGGAAAGGTG ATTGGGGAAG-3' (reverse)), generated
a 590-bp fragment that spanned exons 6, 7, intron 7, exon
8 and a part of the 3'-UTR. The conditions for the ampli-
fication reactions for exons 3, 4 were as previously
described [15] and the conditions for the amplification
reactions for 5'URR and 8-3'UTR fragments, were as fol-
lows: 100 ng of DNA, 1 μM of each primer: 200 μM of
each dNTP (Promega, Madison, WI) and 0.5 U Taq
polymerase in 10× buffer (Fisher Scientific, Suwanee,
GA). The 5'URR and 8-3'UTR PCR procedure was as fol-
lows: an initial denaturation step at 95°C for 5 min, and
amplification for 35 cycles at 94°C for 1 min, 60°C for 1
min, 72°C for 1.30 min, followed by a final extension
step at 72°C for 10 min, except, for 5'URR, the annealing
was 64°C for 45 sec. PCR products were electrophoresed
on 1% agarose gel.
Sequencing and statistical analysis
All PCR products were purified using Qiagen gel extrac-
tion Kits (Chatsworth, CA). Sequencing was performed in
both directions by Big Dye Terminator v.3 (Applied Bio-
systems) on an ABI 3100 Automated sequencer (Applied
Biosystems), using PCR primers for all studied exons and
internal sequencing primers specifically for 5'URR
(5HLAGPRO  5'-GGCTCTCAGGG TCTCAGGCCCCAC-
3'(forward) and HLAGEX1REV 5'-GGCCGTTTCCCTCCT-
GAC-3' (reverse)). Sequencing results were analyzed using
nucleotide-nucleotide BLAST searches. Also, sequences
were aligned with previously published nucleotide
sequences of Geraghty et al.,[16]. Restriction analysis was
used to validate all sequence variants including the ampli-
fied PCR products spanning exons 6, 7 and 8 including
intron 7 and part of 3-UTR that was digested with Pst I
enzyme according to the manufacture's instructions
(Promega). The digested products were subjected to 2%
agarose gel electrophoresis and detected by staining with
ethidium bromide. To assess differences between propor-
tions in each of the HLA-G variant within each studied
exon among HIV-1 non-transmitting and transmitting
mother-child pairs, Fisher' exact test was applied with cor-
responding two-sided p-values, odds ratio (OR) and 95%
confidence intervals (CIs). To assess overall difference
between the exons, Pearson Chi-square test was used with
respect to frequencies of the HLA-G DNA sequence simi-
larities and dissimilarities between HIV-1 non-transmit-
ting and transmitting mother-child pairs within and
among exons and results were declared significant at an α
= 0.05 using the SAS release 9.1.
Definitions of similarity/dissimilarity HLA-G DNA 
sequence variant
Mother-child pairs were considered similar in HLA-G
DNA sequence variant if both the mother and child were
homozygous for that allele, heterozygous for the same
variant within each of the studied exons, with reference to
previously published HLA-G DNA sequence by Geraghty
et al.,[16]. Mother-child pairs who shared only one variant
that is heterozygous, or pairs in which the child was
homozygous for that allele while the mother was not, was
considered as dissimilarity of the HLA-G DNA sequence
variants. Furthermore, mother-child pairs was defined as
a HLA-G DNA sequence variant dissimilar if no shared
HLA-G DNA sequence variants were identified between
the mother and the child within the studied exons of the
HLA-G gene.AIDS Research and Therapy 2006, 3:28 http://www.aidsrestherapy.com/content/3/1/28
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Results and discussion
Thirty-four samples of mother-child pairs (68 samples)
were selected as described above, which included 14 pairs
of HIV-1-infected mothers and their uninfected children
and 20 pairs of mothers and children who were HIV-1-
infected. Analysis of the HLA-G DNA sequences of exons
2, 3, 4, 6, 7, a part of 8-3'UTR and a part of 5'URR span-
ning exon 1 from these samples was performed. All
sequences and positions were referenced with the wild-
type HLA-G sequence of Geragthy et al., [16]. Twenty-one
HLA-G sequence variants were observed as shown in
Table 1. Seven out of 21 (33%) of the observed variants
were previously described [7,8,14,18,19]. Fourteen out of
21 (67%) variants, (G634C, 714insT, C1486G, C1486A,
G2575A, T2577A, C2614A, C2622A, 3401insC, G3579A,
G3585T, C3619G, T3742A, and C3743T) (Table 1; Fig-
ures 1 and 2), were not previously reported.
A heterozygous dissimilarity at nucleotide position
C634G was observed between the pairs of mothers and
children among the HIV-1-non-transmitting group, while
homozygous similarity at nucleotide position C634C was
observed among transmitting mother-child pairs in the
5'URR of the HLA-G gene (Figure 1A and 1B). Further-
more, a dissimilar insertion of either G in mother to T in
child or T in mother to G in child at nucleotide position
714 was found among the HIV-1 non-transmitting
mother-child pairs, while mother-child pairs with similar
714insT/G or G/G were observed among the transmitting
group (Figure 1C,D and 1E).
In addition, analyses of DNA variants in exon regions 2, 3,
4, 6, 7 and 8-3'UTR of the HLA-G gene were performed to
elucidate the association of the polymorphisms with HIV-
1 transmission and results are shown in Table 1. There
were no statistically significant associations of HLA-G
gene variants in exons 3, 4, 6 and 7 with HIV-1-perinatal
transmission among our studied samples (Table 2). In
contrast, there was a statistically significant association of
dissimilarity of the HLA-G DNA sequence variants among
our studied exon 8-3'UTR samples (Table 2; Figure 2A,B,C
and 2D) at nucleotide positions T3742A, C3743T,
G3777C (P = 0.001) with decreased risk of perinatal HIV
transmission. Dissimilarities in the HLA-G exon 8-3'UTR
at nucleotide position C3743T was highly frequent
among the non-transmitting mother-child pairs, 85.7%
(12/14-were dissimilar) than the transmitting mother-
child pairs 14.3% (2/14-were dissimilar) with decreased
risk of perinatal HIV-1 transmission (OR 0.02 [95% CI,
0.00–0.15] P = 0.00001). Validation of the amplified PCR
products spanning HLA-G exons 6, 7, and 8-3'UTR by
RFLP, using Pst  I restriction enzyme resulted in 85.7%
(12/14) of the mother-child pairs showing dissimilarities
of banding profiles among the HIV-1-non-transmitting
group and 90% (18/20) similarity of banding profiles
among the HIV-transmitting mother-child pairs (Figure
3).
This study suggests the association of the HLA-G sequence
variants with increased or decreased risk of perinatal HIV-
1 transmission. All mutations observed in this study are
Table 1: Variations in HLA-G DNA sequence observed among HIV-1-transmitting and non-transmitting mother-child pairs.
Exons Codons Nucleotide positions  Nucleotide substitutions* Amino acid changes 
5'URR --- 634 C/G C→GN o n e
5'URR --- 714 ins T,G insT,G None
2 α-1-domain 31 1074 A/T A→TT h r - t o - S e r
2 α-1-domain 57 1154 G/A G→A Pro-to-Pro
3 α-2-domain 93 1486 C/G C→G His-to-Asp
3 α-2-domain 93 1486 C/A C→A His-to-Asp
3 α-2-domain 93 1488 C/T C→TN o n e  ( H i s )
3 α-2-domain 107 1528 G/A G→A Gly-to-Arg
3 α-2-domain 110 1537 C/A C→AL e u - t o - I l e
3 α-2-domain 130 1597 del C del C Leu→frameshift
4 α-3-domain 256 2575 G/A G→A Arg-to-Lys
4 α-3-domain 257 2577 T/A T→A Tyr-to-Asn
4 α-3-domain 269 2614 C/A C→A Pro-to-His
4 α-3-domain 272 2622 C/A C→AL e u - t o - M e t
Intron 6 3401 ins C ins C None
Intron 7 3579 G/A G→AN o n e
3585 G/T G→TN o n e
3619 C/G C→GN o n e
8 (3'UTR) 3742 T/A T→A instability of mRNA
8 (3'UTR) 3743 C/T Del 14 bp instability of mRNA
8 (3'UTR) 3777 G/C G→C instability of mRNA
*Polymorphisms are indicated with reference to the wild-type HLA 6.0 sequence previously published by Geraghty (1987).AIDS Research and Therapy 2006, 3:28 http://www.aidsrestherapy.com/content/3/1/28
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present in the HLA-G mRNA isoforms and these mRNA
isoforms are abundant transcripts in the placental tissue
[7]. Previously, we have reported the association of a con-
servative mutation in HLA-G exon 2 (which encodes for
the alpha-1-domain), (OR, 0.5 [95% CI, 0.00–0.47] p =
0.003) codon 57 with increased risk of perinatal transmis-
sion of HIV-1 [9]. Although, the mutation in exon 2
region was considered as a silent mutation, a study by
Duan et al., [17] has demonstrated that a silent mutation
effects human dopamine receptor D2 stability and synthe-
sis of the receptor. In contrast, a study by Matte et al., [18]
that investigated HLA-G gene concordance/discordance in
African population of MTCT found no association of the
mutation in exon 2 region at codon 57 with perinatal
HIV-1 transmission. The striking difference in the results
may be explained by the population structure used in
their study (90% of the subjects in their study were of
Shona ethnicity, which may represent a homogenous
ancestral group or considered an isolated population). In
general, homogeneous populations have relatively low
frequencies of genetic variability than the heterogeneous
populations and certain mutations may not play a role in
disease protection in isolated populations compared to
mixed populations. Furthermore, the apparent discrepan-
cies between Matte et al., [18] study and our previous
results could be further attributed to the definition of con-
cordance and discordance. Nevertheless, this study data
suggests that HLA-G gene mutations in the 5'URR alone or
in combination with exon 8-3'UTR among HIV infected
mother/uninfected child pairs that exhibited mismatch-
ing in the HLA-G DNA sequence may be associated with
decrease in the risk of mother-child transmission of HIV-
1. Mutations in HLA-G gene, particularly in 3' UTR region,
may enhance the reduction of the expression of HLA-G
Sequence electropherograms obtained from 8-3' untrans- lated region showing polymorphisms at nucleotide positions  3742, 3743 and 3777 Figure 2
Sequence electropherograms obtained from 8-3' untrans-
lated region showing polymorphisms at nucleotide positions 
3742, 3743 and 3777. A-B: Forward strand sequences and 
arrows indicating nucleotide changes of T→A and G→C. 
Underlined is the +/-14bp. C-D: Sequences showing a nucle-
otide change of C→T indicated by arrows. Notably, C3743T 
sequence variant was observed at a high dissimilarity 











Sequence electropherograms obtained from HLA-G DNA 5'  untranslated regulatory region showing polymorphisms at  nucleotide positions 634 and 714 Figure 1
Sequence electropherograms obtained from HLA-G DNA 5' 
untranslated regulatory region showing polymorphisms at 
nucleotide positions 634 and 714. A-B: Reverse strand 
sequences and arrows indicating a nucleotide change of 
C→G observed between mother-child pairs among the HIV-
1 non-transmitting group. C-D: Forward strand sequences 
showing insertions of either T or G. E: Reverse strand 
sequence and underlined is the CCAAT box. Interestingly, dis-
similarities of the 714insT/G were observed between the 
mother child pairs of the HIV-1-non-transmitting group 
while, either 714insG/G or mother-child pairs with similar 
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gene and hence play a role in the in-utero-HIV infectivity.
A study has demonstrated that 14-bp deletion-insertion
polymorphisms in the 3' UT region of the HLA-G gene
influences HLA-G mRNA stability [19]. Other studies
have shown that down regulation of the surface expres-
sion of HLA-G gene by viral immunoevasion of the pla-
cental MHC class I molecules like herpes simplex and
cytomegalovirus results in viral replication and infection
[20,21].
Surprisingly, we did not observe any previously described
polymorphisms by Ober [22] and Matte [23], except one
polymorphism reported by Hviid [8] at 714insG in the
portion of the studied sequence of the untranslated regu-
latory and full length of exon 1 regions of the HLA-G gene.
Nevertheless, 98–99% of the same regions in our study
matched with the previously published sequence of that
region by Geraghty et al., [16]. We observed six and four
nucleotide sequence variations within exon 3 and exon 4
regions respectively. This is a striking difference between
this study and previously reported 31 variations in exon 3
by van der Ven et al., [15,24]. However, the number of var-
iations in exon 3 region was similar to those reports by
Ishitani et al., [25] and Matte et al., [23]. Of note is that all
the observed nucleotide changes in exon 4 region resulted
in amino acid changes and three of the six observed nucle-
Table 2: HLA-G DNA sequence variant dissimilarities/similarities between Mother-child pairs and risk of perinatal HIV-1 transmission
HLA-G Mutation Position N = 20 HIV-1 Transmitting group N = 14 HIV-1-non-Transmitting group P-Value (2-sided) OR (95%CI)
Exon-2
Codon 31 Dissimilar 2 (10.0%)* 2 (14.3%)* 0.987 0.67 [0.08–5.39]
Similar 18 (90.0%) 12 (85.7%)
Codon 57 Dissimilar 8 (40.0%) 13 (92.9%) 0.003 0.05 [0.00–0.47]9
Similar 12 (60.0%) 1 (7.1%)
Exon-3
Codon 93 Dissimilar 4 (20.0%) 6 (42.9%) 0.290 0.33 [0.07–1.53]
Similar 16 (80.0%) 8 (57.1%)
Codon 107 Dissimilar 1 (5.0%) 0 (0.0%) 0.806 2.23 [0.09–58.81]
Similar 19 (95.0%) 14(100.0%)
Codon 110 Dissimilar 5 (25.0%) 3 (21.4%) 0.866 1.22 [0.24–6.23]
Similar 15 (75.0%) 11 (78.6%)
Codon 130 Dissimilar 1 (5.0%) 0 (0.0%) 0.806 2.23 [0.09–58.81]
Similar 19 (95.0%) 14 (100.0%)
Exon-4
Codon 256 Dissimilar 10 (50.0%) 2 (14.3%) 0.060 6.0 [1.06–34.00]
Similar 10 (50.0%) 12 (85.7%)
Codon 257 Dissimilar 10 (50.0%) 3 (21.4%) 0.150 3.67 [0.78–17.25]
Similar 10 (50.0%) 11 (78.6%)
Codon 269 Dissimilar 5 (25.0%) 0 (0.0%) 0.174 10.3 [0.52–203.07]
Similar 15 (75.0%) 14 100.0%)
Codon 272 Dissimilar 0 (0.0%) 2 (14.3%) 0.359 0.12 [0.01–2.75]
Similar 20 (100.0%) 12 (85.7%)
Intron 6
3401 Dissimilar 0 (0.0%) 0 (0.0%) undefined undefined
Similar 20 (100.0%) 14 (100.0%)
Intron 7
3579 Dissimilar 2(90.0%) 5 (35.7%) 0.090 0.2 [0.03–1.24]
Similar 18 10.0%) 9 (64.3%)
3585 Dissimilar 9 (45.0%) 6 (42.9%) 0.820 1.09 [0.28–4.32]
Similar 11 (55.0%) 8 (57.1%)
3619 Dissimilar 11 (55.0%) 6 (42.9%) 0.727 1.63 [0.41–6.46]
Similar 9 (45.0%) 8 (57.1%)
Exon 8-3UTR
3742 Dissimilar 4 (20.0%) 10 (71.4%) 0.004 0.1 [0.02–0.49]
Similar 16 (80.0%) 4 (28.6%)
3743 Dissimilar 2 (10.0%) 12 (85.7%) 0.00001 0.02 [0.00–0.15]
Similar 18 (90.0%) 2 (14.3%)
3777 Dissimilar 5 (25.0%) 9 (64.3%) 0.03 0.19 [0.04–0.82]
Similar 15 (75.0%) 5 (35.7%)
*Percentage of similarity and dissimilarity; N, number of pairs in the given group;
Data from 34 mother-child pairs with HLA-G DNA sequence variants as compared to the previously published wild-type HLA 6.0 sequence by 
Geraghty (1987). Mother-child pairs matching with the same HLAG DNA sequence variants at the above HLA-G sequence positions are 
considered similar; Mother with a mismatched HLAG DNA sequence variants at one or more of these positions with the child is considered 
dissimilar.AIDS Research and Therapy 2006, 3:28 http://www.aidsrestherapy.com/content/3/1/28
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otide changes in exon 3 region resulted in amino acid
change as well. No nucleotide variation was observed in
exons 6 and 7 regions. An insertion of C at position 3401
in intron 6 region and three nucleotide changes, G3579A,
G3585T, and C3619G, in intron 7 were observed in our
samples. In exon 8-3' UTR, we observed four nucleotide
changes including the 14-bp insertion/deletion. To our
knowledge, these nucleotide changes in introns 6, 7 and
the two nucleotide changes at 3742 and 3743 positions of
8-3'UTR (Tables 1, 2) have not been previously reported.
The polymorphisms at nucleotide positions 3742 and
3743 that were observed in some sequences of our studied
samples with the 14-bp deletions, may be considered as a
precursor to the occurrence of the 14-bp deletion in the
HLA-G gene and could possibly influence mRNA stability.
Interestingly, the dissimilarity of the HLA-G sequence var-
iants at nucleotide position C634G and 714insT/G
observed between the mother and child of HIV-1-non-
transmitting group may be in linkage disequilibrium with
another variant that confers low risk of HIV perinatal
transmission. Although we do not have functional data to
correlate this assumption, these polymorphisms identi-
fied in 5' URR of HLA-G gene in this study, may play an
important role in the pre-transcription due to the location
of these variants, which are up and downstream of the
CCAAT box respectively. In addition, the 714insT or G is
closely flanked by an interferon response factor-1 binding
motif at the upstream regulatory element of HLA-G gene.
Taken together, the data from this study fits the "Trojan
exosome hypothesis" to some degree, which predicts rela-
tively efficient retroviral transmission between individu-
als who are histocompatible and relatively inefficient
retroviral transmission between individuals who are his-
toincompatible [26]. Given that HLA-G gene is primarily
expressed during fetal life, it could be envisaged that dur-
ing gestation, a HIV-1-infected mother could transmit the
virus to her fetus. This intrauterine exposure to HIV-1
virus may be a powerful selective force that could result in
a polymorphism advantage at this HLA-G locus of fetuses,
which can be presented with a wider variety of foreign
peptides to the T-cell receptors. As a result, fetuses with a
high similarity of HLA-G sequence variants with their
mothers may be more susceptible to intrauterine HIV-1
infection compare to fetuses with HLA-G sequence vari-
ants that are relatively dissimilar but unlikely to be recog-
nized as foreign by the maternal immune system. This
deduced scenario is similar to the previously hypothe-
sized scenario by van der Ven and Ober regarding HLA-G
allogenic response [15].
Conclusion
Based on these results, it is increasingly clear that HLA-G
variants in exon 8-UTR, either alone or in combination
with exon 2 codon 57 that was previously reported [9]
and the 5' UTR could influence the risk of MTCT of HIV-1
infection. In addition, it is tempting to speculate that
these observed HLA-G sequence variants may play a role
in the in-utero HIV-1 transmission, even in the presence of
other recognized risk factors [27-30]. However, the lim-
ited sample size of this data set suggests that the results
should be interpreted cautiously. Future studies are
required in a larger population of samples to determine
the full impact of these HLA-G variants in perinatal HIV-1
transmission.
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